Xiaowen Peng
Overview
Explore the profile of Xiaowen Peng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
87
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peng X, Holler C, Alves A, Oliviera M, Speake M, Pugliese A, et al.
Bioorg Med Chem Lett
. 2023 Dec;
98:129595.
PMID: 38141860
Screening a library of >100,000 compounds identified the substituted tetrazole compound 1 as a selective TRPML1 agonist. Both enantiomers of compound 1 were separated and profiled in vitro and in...
2.
Fei J, Chen S, Song X, Liang Y, Duan K, Peng X, et al.
FASEB J
. 2023 Nov;
38(1):e23340.
PMID: 38031959
Facial nerve regeneration still lacks a well-defined and practical clinical intervention. The survival of central facial motoneuron is a critical component in the successful peripheral facial nerve regeneration. Endogenous GDNF...
3.
Peng X, Lanter J, Chen A, Brand M, Wozniak M, Hoekman S, et al.
Bioorg Med Chem Lett
. 2022 Nov;
80:129048.
PMID: 36368496
Phenotypic screening of an annotated small molecule library and initial SAR studies identified compound 2 as a robust enhancer of progranulin secretion. Detailed SAR development on conformationally restricted carbamate isosteres...
4.
Zhou J, Peng X, Li X, Kong X
Dis Markers
. 2022 Mar;
2021:2174290.
PMID: 35356669
In the current study, a Cu(II) coordination polymer (CP) has been created in success with the solvothermal reaction between an asymmetrical rigid N-heterocyclic carboxylatic acid (HL) and Cu(NO)·3HO in the...
5.
Huang Y, Luo Y, Ou W, Wang Y, Dong D, Peng X, et al.
Cancer Cell Int
. 2022 Feb;
22(1):55.
PMID: 35109830
No abstract available.
6.
Huang Y, Luo Y, Ou W, Wang Y, Dong D, Peng X, et al.
Cancer Cell Int
. 2021 Oct;
21(1):528.
PMID: 34641864
Background: Exosome-mediated crosstalk between cancer cells and immune cells contributes to tumor growth. In this study, we investigated the mechanism underlying the exosome-mediated immune escape of colorectal cancer (CRC) cells...
7.
Luo Y, Sun F, Peng X, Dong D, Ou W, Xie Y, et al.
Int J Gen Med
. 2021 Sep;
14:4745-4756.
PMID: 34466019
Objective: To identify the value of key differentially expressed genes (DEGs) regulated by differentially methylated regions (DMRs) in predicting the prognosis of human colon cancer. Materials And Methods: RNA sequencing...
8.
Owens C, Brasher B, Polemeropoulos A, Rhodin M, McAllister N, Peng X, et al.
Antimicrob Agents Chemother
. 2016 Aug;
60(10):6207-15.
PMID: 27503640
EDP-239, a novel hepatitis C virus (HCV) inhibitor targeting nonstructural protein 5A (NS5A), has been investigated in vitro and in vivo EDP-239 is a potent, selective inhibitor with potency at...
9.
Hoveyda H, Marsault E, Gagnon R, Mathieu A, Vezina M, Landry A, et al.
J Med Chem
. 2011 Nov;
54(24):8305-20.
PMID: 22106937
High-throughput screening of Tranzyme Pharma's proprietary macrocycle library using the aequorin Ca2+-bioluminescence assay against the human ghrelin receptor (GRLN) led to the discovery of novel agonists against this G-protein coupled...
10.
Marsault E, Hoveyda H, Gagnon R, Peterson M, Vezina M, Saint-Louis C, et al.
Bioorg Med Chem Lett
. 2008 Jul;
18(16):4731-5.
PMID: 18640834
A new method for solid phase parallel synthesis of chemically and conformationally diverse macrocyclic peptidomimetics is reported. A key feature of the method is access to broad chemical and conformational...